JW Pharmaceutical Corporation

KSE 001060.KS

JW Pharmaceutical Corporation Revenue for the year ending December 31, 2023: USD 574.87 M

JW Pharmaceutical Corporation Revenue is USD 574.87 M for the year ending December 31, 2023, a 6.33% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

JW Pharmaceutical Corporation Revenue for the year ending December 31, 2022 was USD 540.64 M, a 6.49% change year over year.
JW Pharmaceutical Corporation Revenue for the year ending December 31, 2021 was USD 507.71 M, a 1.05% change year over year.
JW Pharmaceutical Corporation Revenue for the year ending December 31, 2020 was USD 502.45 M, a 13.99% change year over year.
JW Pharmaceutical Corporation Revenue for the year ending December 31, 2019 was USD 440.77 M, a -8.22% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

KSE: 001060.KS

JW Pharmaceutical Corporation

CEO	Mr. Young-Sub Shin
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	2477, Nambusunhwan-ro
Employees	1,064
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years